散发性急性戊型肝炎血清抗体动态变化和肝脏超微结构的病理观察

为探讨散发性戊型肝炎血清抗体动态变化，应用酶联免疫法（ＥＩＡ）检测了７例急性戊型肝炎患者抗戊型肝炎病毒（ＨＥＶ）ＩｇＧ和ＩｇＭ抗体，并对１例患者进行了肝超微结构病理检测。结果表明，发病后１０天至４５天内抗ＨＥＶ－ＩｇＧ和ＩｇＭ滴度最高，发病第４０天仍有肝细胞肿胀，胞浆空化和线粒体固缩等病理变化。患者血清抗－ＨＥＶＩｇＭ滴度在４５天后逐渐下降，２个月内全部消失，抗－ＨＥＶＩｇＧ消长情况与ＩｇＭ相似，但在７个月时仍有３例（４３％）抗体阳性。     

用重组结构区抗原检测抗丙型肝炎病毒IgM抗体方法的建立

目的检测抗丙型肝炎病毒（ＨＣＶ）结构区蛋白ＩｇＭ抗体。方法采用丙型肝炎病毒Ｃ，Ｅ１，Ｅ２区重组抗原混合包被和分别包被酶标板；用兔抗人γ链血清处理人血清标本，再用固相包被羊抗兔抗体吸附兔抗人γ链－人ＩｇＧ复合物，建立了抗－ＨＣＶＩｇＭ检测方法。结果对７６例丙型肝炎病人血清进行抗－ＨＣＶＩｇＭ检测，同时与逆转录－巢式聚合酶链反应（ＲＴ－ＰＣＲ）检测结果进行比较，两者具有相关性（Ｐ＜０００５）；ＩｇＭ抗体组成分析结果表明采用全片段Ｃ、Ｃ＋Ｅ２区抗原血清标本中的抗－ＨＣＶＩｇＭ检出率分别可达９６６％和１００％。结论ＨＣＶ的Ｃ、Ｅ２重组抗原用于抗－ＨＣＶＩｇＭ检测具有较高的敏感度和特异性。     

丙型肝炎患者血清抗丙型肝炎病毒抗体IgM及HCVRNA检测结果的比较

用酶联免疫吸附试验（ＥＬＩＳＡ）对住院病人抗丙型肝炎病毒抗体（抗－ＨＣＶ）阳性血清标本进行抗－ＨＣＶＩｇＭ的检测，并与ＨＣＶＲＮＡ检测结果比较。结果表明，ＨＣＶＲＮＡ阳性、抗－ＨＣＶ阳性，ＨＣＶＲＮＡ阳性、抗－ＨＣＶ阴性及ＨＣＶＲＮＡ阴性、抗－ＨＣＶ阳性三种类型中均有抗－ＨＣＶＩｇＭ阳性者。结果还表明ＨＣＶＲＮＡ阳性病例的抗－ＨＣＶＩｇＭ阳性率明显高于ＨＣＶＲＮＡ阴性的病例（Ｐ＜０．０５），在临床诊断上ＨＣＶＲＮＡ阳性与阴性病例的肝病大多数为急性肝炎（ＡＨ）和慢性活动性肝炎（ＣＡＨ），ＨＣＶＲＮＡ阳性与阴性比较，各类肝病的病例数无明显差别。     

831名健康青年庚型肝炎病毒和人免疫缺陷病毒感染的调查

目的了解我国健康青年中庚型肝炎病毒（ＨＧＶ）和人免疫缺陷病毒的感染情况。方法采用酶联免疫法（ＥＩＡ）检测６省８３１名健康青年血清中的ＨＧＶ和ＨＩＶ抗体，对抗－ＨＧＶＩｇＧ阳性的血清再用逆转录－巢式聚合酶链反应（ＲＴ－ＰＣＲ）检测ＨＧＶＲＮＡ。结果发现抗－ＨＣＶＩｇＧ阳性率为２５３％（２１／８３１），２１例阳性者中ＨＧＶＲＮＡ阳性８例，两者符合率为３８１％；抗－ＨＩＶ均阴性。结论我国健康青年人群中确实存在ＨＧＶ感染。     

巨细胞病毒感染与可溶性白细胞介素2受体的关系

应用酶联免疫吸附试验（ＥＬＩＳＡ）对１０４例育龄妇女的血清进行了巨细胞病毒（ＨＣＭＶ）ＩｇＧ、ＩｇＭ抗体的检测，同时用ＥＬＩＳＡ双抗体夹心法测定了不同感染状态下血清中可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）的水平，并将ｓＩＬ－２Ｒ水平与未感染ＨＣＭＶ的正常育龄妇女进行了比较。结果，育龄妇女中抗－ＨＣＭＶＩｇＧ的阳性率为８９．４％，ＩｇＭ的阳性率为９．６％，感染ＨＣＭＶ的妇女血清中ｓＩＬ－２Ｒ水平均大于未感染的对照组（１７８．１±５７．３Ｕ／ｍｌ），Ｐ＜０．０５，其中ＩｇＭ阳性者和ＩｇＭ、ＩｇＧ同时阳性者血清中ｓＩＬ－２Ｒ水平最高，分别为９１０±４６５．６Ｕ／ｍｌ和９０５±３４７．８Ｕ／ｍｌ，两者间的差异无显著性意义（Ｐ＞０．０５），但均大于仅抗－ＨＣＭＶＩｇＧ阳性者（４４６．８±１５８．９Ｕ／ｍｌ），Ｐ均＜０．０５。表明，ＨＣＭＶ感染可致ｓＩＬ－２Ｒ水平升高，并且活动性感染者上升明显。提示：ｓＩＬ－２Ｒ可能参与了ＨＣＭＶ的免疫致病机制。     

散发性急性戊型肝炎血清抗体动态变化和肝脏超微…

为探讨散发性戊型肝为血清抗体动态变化，应用酶联免疫法（ＥＩＡ）检测了７例急性戊型肝炎抗戊型肝炎病毒（ＨＥＶ）ＩｇＧ和ＩｇＭ抗体、并对１例２进行了肝超微结构病理检测，结果表明，发病１０天至４５天内抗ＨＥＶ－ＩｇＧ和ＩｇＭ滴度最高，发病第４０天仍有肝细胞肿胀，胞浆空化和线粒体固缩等病理变化。患者轿清抗－ＨＥＶＩｇＭ滴度在４５天后逐渐下降，２个月内全中消失，抗－ＨＥＶＩｇＭ滴度在４５天后逐渐下降，２个月     

831名健康青年庚型肝炎病毒和人免疫缺陷病毒感染？…

目的 了解我国健康青年中庚型肝炎病毒（ＨＧＶ）和人免疫缺陷病毒的感染情况。方法 采用酶联免疫法（ＥＩＡ）检测６省８３１名健康青年血清中的ＨＧＶ和ＨＩＶ抗体，对抗－ＨＧＶＩｇＧ阳性的血清再用逆转录－巢式聚合酶链反应（ＲＴ－ＰＣＲ）检测ＨＧＶＲＮＡ。结果 发现抗－ＨＧＶ ＩｇＧ阳性率为２．５３％（２１／８３１），２１例阳性者中ＨＧＶ ＲＮＡ阳性８例，两者符合率为３８．１％；抗－ＨＩＶ均阴性。结论 我     

庚型肝炎病毒IgM抗体检测方法的建立及其临床意义

目的建立一种早期、快速诊断庚型肝炎的血清学检测方法。方法以辣根过氧化物酶标记庚型肝炎病毒（ＨＧＶ）多肽ＮＳ３,ＮＳ５区段抗原,建立了捕获酶联免疫吸附试验（ＥＬＩＳＡ）,用于检测血清中ＨＧＶＩｇＭ抗体。结果本法不受特异性ＩｇＧ的竞争和类风湿因子的干扰;与其它致肝炎的病毒（ＨＡＶ、ＨＢＶ、ＨＣＶ、ＨＥＶ、ＣＭＶ、ＥＢＶ）无交叉反应。检测４６例非甲、乙、丙、戊型肝炎患者血清,抗－ＨＧＶＩｇＭ阳性１４例,阳性率３０．４３％,其中,６例同时为ＨＧＶＲＮＡ阳性,阳性符合率为４２．８６％（６／１４）,检测１２例庚型肝炎病人双份血清,其中,急性期血ＨＧＶＩｇＭ抗体均为阳性。结论该法检测ＨＧＶＩｇＭ抗体特异性强,敏感性高,且简便快速,适用于临床对庚型肝炎新近感染的早期诊断,有推广应用价值。     

丙型肝炎病毒感染者中抗病毒IgM检测的意义

建立了抗ＨＣＶＩｇＭ间接ＥＬＩＳＡ方法，并用之检测ＨＣＶ不同感染人群。抗ＨＣＶＩｇＭ在不同感染人群中的检出率变化很大。急性输血后丙型肝炎患者检出率可高达９３．８％，而正常献血员中可低至０．６８％。比较抗ＨＣＶＩｇＭ和抗ＬｇＧ阳性中ＨＣＶＲＮＡ的检测结果发现，抗ＩｇＭ阳性者中，不同ＨＣＶ感染人群的ＨＣＶＲＮＡ检出率很高（９３．０％～１００％）；而ＩｇＧ阳性者中ＨＣＶＲＮＡ的检出率变化很大（３７．５％～９３．８％）。在４３例血液透析者中抗ＩｇＭ与ＨＣＶＲＮＡ检测的一致性为８３．７％；抗ＩｇＭ与抗ＩｇＧ检测的一致性为８８．４％，结果提示：（１）抗ＨＣＶＩｇＭ与ＨＣＶ活跃复制有关，（２）抗ＨＣＶＩｇＭ与抗ＨＣＶＩｇＧ检出不完全一致。因此，临床检测抗ＨＣＶＩｇＭ有其特殊意义。     

不同人群庚型肝炎病毒感染状况分析

为了解不同人群庚型肝炎病毒（ＨＧＶ）感染状况，采用优化的ＨＧＶＮＳ５区两条合成肽为抗原，建立间接酶联免疫吸附试验（ＥＬＩＳＡ），检测了１２０９例不同人群血清中抗－ＨＧＶＩｇＧ，总阳性率为３．８％，其中非Ａ～Ｅ型肝炎患者抗－ＨＧＶＩｇＧ阳性率最高，为２０．５％，明显高于自然人群的０．８％和其它肝炎患者（Ａ～Ｅ型）的３．３％，丙型肝炎患者中抗－ＨＧＶＩｇＧ阳性率亦较高，为８．０％。职业献血员抗－ＨＧＶＩｇＧ阳性率３．４％高于义务献血员０．０％。性病患者阳性率为３．６％，有静脉吸毒史的ＨＩＶ感染者阳性率亦较高，为８．０％。结果表明，ＨＧＶ在我国有较高的感染率；ＨＧＶ可能为非Ａ～Ｅ型肝炎的重要致病因子；职业献血员和有血液接触史者ＨＧＶ感染率较高，提示血源应严格筛选     

IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein

To develop an enzyme immunoassay (EIA) for IgM antibody to hepatitis E virus (HEV) (IgM anti-HEV) and IgG antibody to HEV (IgG anti-HEV), a synthetic gene encoding several liner immuno-dominant antigenic epitopes from HEV structural proteins was assembled as a chimeric recombinant mosaic protein (Mpr) with glutathione S-transferase and used as an immunodiagnostic target. In addition, a neutralization confirmation test was developed using individual synthetic peptides. Among 614 patients with acute hepatitis from 10 geographically distinct outbreaks, IgG anti-HEV was found in 546 (88.9%), with a range of 77–100% depending on the outbreak. Of 130 patients tested for IgM anti-HEV, 126 (96.9%) were positive. Among patients tested within 4 months of onset of jaundice, 37/37 (100%) were IgG anti-HEV positive. For patients from whom sera were collected 1–16 days after onset of jaundice, the geometric mean IgG titer (GMT) was 1:47,000; the GMT increased to 1:70,710 30–40 days after onset of jaundice and decreased to 1:1,778 3–4 months after the onset of jaundice. For patients tested 6–8 months after onset of jaundice, 11/12 (92%) were IgG anti-HEV positive, and the GMT was 1:2,908. IgM anti-HEV was detected in 43/43 (100%) sera collected 1–40 days after onset of jaundice, and the GMT for IgM anti-HEV was 1:10,000 at that time. For sera collected 3–4 and 6–12 months after onset of jaundice, 7/14 (50%) and 5/12 (40%) respectively, were IgM anti-HEV positive. In conclusion, an artificial mosaic protein composed of linear antigenic epitopes from open reading frame 2 (ORF2) and ORF3 of HEV has been successfully applied to the development of a sensitive and specific EIA for the detection of IgG and IgM anti-HEV activity. These assays were used for the verification of HEV infection in outbreak settings and for the diagnosis of HEV infection in sporadic cases. © 1996 Wiley-Liss, Inc.     

Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis.

Serum samples were taken from 57 patients with sporadic non-A, -B, and -C (Non A, B, C) acute hepatitis at different times after onset of the disease and tested for the presence of the hepatitis E virus (HEV) RNA, IgM, and low avidity IgG antibodies. The viral antibodies were detected using two ELISA. One assay (GL) was produced using a mixture of recombinant peptides specified by ORF2 and ORF3 of the viral genome. The other was produced with an ORF2 specified peptide, pE2. The latter occurs naturally as homodimer, it is recognized strongly in its dimeric form by human sera and, in the primate model, it confers protection against experimental HEV infection. Nineteen samples were positive for one or more of these acute markers of HEV infection, 14 of which were acute sera with elevated ALT levels and 5 were convalescent sera with normal ALT level. The results showed that icteric phase of sporadic hepatitis lasts for about 17 days and it coincides with a period when viremia is subsiding as HEV antibodies are developing. Viremia was intermittent and all but one of the 5 instances were confined to the icteric phase with elevated ALT levels. On two of these occasions, viremia preceded detection of HEV antibody, on another 2 occasions it was concurrent with the detection of pE2 specific IgM and/or low avidity IgG and only in one case of protracted viremia was the viral genome detected concurrently with avid pE2 IgG antibody. Ten (71%) of the 14 acute sera were reactive for pE2 IgM, eight (57%) were reactive for low avidity pE2 IgG, and six (43%) for the GL IgM. The sensitivity for the diagnosis of acute hepatitis E may be increased to 87% by combining pE2 IgM and viremia. GL IgM was detected later, but persisted for a longer period of time than the pE2 antibodies, and it was the only acute antibody detected in the convalescent sera.     

Hepatitis E virus seroprevalence in acute viral hepatitis in a developed country confirmed by a supplemental assay

Hepatitis E virus (HEV) infection is prevalent among cases of acute viral hepatitis in young adults in developing countries. HEV infection is not restricted to endemic areas, but would appear to be worldwide in distribution. In order to document the incidence of HEV infection in acute hepatitis cases in a developed country, IgG and IgM anti-HEV antibodies and HEV RNA were tested in 101 Caucasian patients with acute viral hepatitis; 92 of these cases had markers of acute viral hepatitis other than HEV. Forty-seven (46.5%) cases had IgG anti-HEV; IgM anti-HEV and HEV viremia were not detected. As the incidence of anti-HEV was higher than would be expected, the possibility of the occurrence of false positive results was subsequently investigated. Supplemental antibody testing, using a broadly reactive epitope region, reduced the frequency of anti-HEV to 17%. Therefore, supplemental antibody testing confirms the hepatitis E virus seroprevalence in a developed country. Since IgM anti-HEV and HEV viremia were not detected, persons with IgG anti-HEV may be “subclinical HEV cases,” or have long-lived antibodies in their circulation. © 1996 Wiley-Liss, Inc.     

Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response

Sequential sera were collected from 18 acute cases of UK-acquired hepatitis E. The virus strains in all cases were of genotype 3. The IgM and IgG response to acute infection were documented over time using EIA kits based on a peptide antigen, pE2, which is derived from a genotype 1 strain of hepatitis E virus (HEV). Ninety-five percentage of acute sera were IgM positive; after 6 months or more only 12% remained positive. The kit was adapted to quantify the IgG response (in WHO U/ml) and to determine antibody avidity. Following acute infection, anti-HEV IgG concentrations rose between 6.9- and 90-fold. IgG avidity was low (<25%) in most acute sera. After 6 months IgG avidity was greater than 50% in all cases. One patient with a poor IgM response and high avidity antibody in acute sera may have had a second HEV infection. Taken together, these results confirm that the pE2-based EIA kits are suitable for diagnosing acute HEV genotype 3 infection. With simple modifications the IgG kit can measure anti-HEV concentration and avidity, which can be used to confirm acute infection.     

急性肝炎恢复期血清检测抗戊型肝炎病毒抗体及RNA的临床诊断意义

目的 在急性非甲-戊型肝炎患者中进一步追踪检测不同时期血清抗戊型肝炎病毒(HEV)IgG，以明确临床诊断。方法 用美国Genelabs公司和北京万泰公司抗HEV诊断试剂检测抗HEV，用PCR方法检测HEVRNA，并进行基因序列分析。结果 95例入院首次血清学诊断为急性非甲-戊型肝炎患者中，在住院后11～25d、25～35d分别测定血清抗HEV,16例血清抗HEV阳性(万泰公司)，急性期血清HEVRNA检测10例HEVRNA阳性，经核苷酸序列分析证明，其中4例为Ⅰ型HEV感染，6例为Ⅳ型HEV感染。GenekLbs诊断试剂检测12例抗HEV阳性，7例HEVRNA阳性，其中4例是HEVⅠ型病毒感染，3例是HEV Ⅳ病毒感染。结论 对非甲-戊型肝炎患者进行急性期HEV RNA检测和恢复期抗HEV检测可以进一步明确病原学诊断，在这部分患者中存在HEV不同基因型感染。可能是HEV感染漏诊的原因之一。     

几种戊型肝炎试剂的比较及IgG抗体定量方法的建立

目的 利用多种抗戊型肝炎病毒(HEV)IgM、IgG检测试剂对戊型肝炎恢复期血清进行确认,建立戊型肝炎病毒ISG抗体的定量检测方法,初步应用于戊型肝炎疫苗接种后抗体效价检测.方法 应用多种抗-HEV IgM、IgG试剂对江苏省确诊的戊型肝炎病人发病后6个月以上的血清样品进行检测;抗-HEV IgG阳性样本应用ORF2 C端抗原和ORF3抗原Western blot进行确认,用WHO抗-HEV Ig标准品标定确认阳性的混合血清抗-HEV IgG的含量,制备抗-HEV IgG定量检测的线性标准品,建立戊型肝炎疫茼免疫后抗体定量检测方法.结果 42份戊型肝炎恢复期血清采用G、K、MP、万泰4种抗-HEV IgG试剂检测的阳性率分别为71.4%、78.6%、92.9%、100%,G试剂阳性率低于MP(X2=5.19,P<0.05)和万泰试剂(χ~2=11.76,P<0.01),K试剂阳性率明显低于万泰试剂(χ~2=7.96,P<0.01);MP、G、X、万泰、K试剂抗-HEV IgM试剂的阳性率分别为21.4%、7.1%、21.4%、64.3%、78.6%;万泰和K试剂的阳性率均明显高于MP(χ~2=15.75,P<0.01;X2=27.43,P<0.01).Western blot确认试验分别有30和18份血清与ORF2、ORF3抗原有阳性反应.13份血清混合为HEV-D01,其抗-HEV IgG浓度经标定为57.94 U/ml.制备了浓度范围为0.077～0.877 U/ml的7个1.5倍系列稀释的定最线性标准品,用于戊肝疫苗临床试验,试验过程中对高、中、低浓度质控品的定量值均在均数±2s范围内,变异系数(cv)分别为16%、16%、12%.结论 不同抗-HEV IgM和IgG试剂之间的质量存在较大差别,建立了抗-HEV IsG定量检测标准品,适用于戊肝疫苗的临床血清抗体IgG定量检测.     

Seroepidemiology of hepatitis E virus in patients with non-A, non-B, non-C hepatitis in Hungary

Many cases of acute hepatitis remain undiagnosed and the hepatitis E virus (HEV) is emerging in industrialized countries. The aim of this study was to assess the role HEV as causative agent in acute non-A, non-B, and non-C hepatitis patients in Hungary. 10.5% of the 264 acute non-A, non-B, and non-C hepatitis patients tested had anti-HEV IgG and 1.9% had anti-HEV IgM as tested by ELISA. After confirmation by Western blot 6.1% of the acute non-A, non-B, and non-C hepatitis patients had anti-HEV IgG antibodies only and 1.1% of the patients had both IgG and IgM. All 19 patients that were positive for anti-HEV IgG and/or IgM tested negative for HEV RNA by PCR. Only a small proportion of the acute hepatitis cases in the southwest of Hungary are assumed to be attributed to HEV infection, however, hepatitis E should be considered along with hepatitis A, B, and C in the diagnosis of acute hepatitis.     

Detection of hepatitis E virus in patients sera in southern Spain

The aim of the present study was to detect acute Hepatitis E virus (HEV) infection in patients with abnormal alanine transaminase (ALT) in which other viral hepatitis infections had been excluded in southern Spain, an area adjacent to regions where this disease is endemic. Of 336 sera tested 30 (8.92%) were positive for IgM antibodies against HEV (anti-HEV IgM) and 7 (2.08%) were negative in a repeated assay. Immunoblot analysis (IBA) was applied to the 37 positive sera in the first assay; its results were positivity for 26 (7.73%), ambiguous for 5 and negative for 6 sera. Amplification of ORF1 and ORF2 of HEV by means of nested RT-PCR was carried out with the 37 sera that were either positive or ambiguous by ELISA; a positive result was obtained only with one serum for the ORF2 protein. IgM antibodies against the HEV ORF2 protein could be a useful marker in the diagnosis of acute infection and a substitute for the determination of viral RNA in serum; this is of both diagnostic and epidemiological importance as it would allow the patients transmitting the infection to be recognized by means of a simple determination of antibodies. The sequence of the ORF2 fragment of HEV occurring in samples taken from both humans and animals amplified in this study has considerable homology with the sequences of HEV strains/isolates of European origin. These results demonstrate that an autochthonous HEV circulates in Spain.     

Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised

BackgroundRecently, cases of chronic hepatitis E have been identified in immunocompromised patients.ObjectivesTo evaluate the prevalence of anti-HEV IgG antibodies and the persistence of HEV-RNA in sera of immunocompromised patients with regular follow-up at Saint-Louis Hospital in Paris, France.Study design307 samples collected from 261 HIV-infected patients and 46 kidney transplant (KT)-patients were retrospectively tested for the presence of the following hepatitis E virus (HEV) infection markers: anti-HEV IgM antibodies, anti-HEV IgG antibodies, anti-HEV IgG avidity index, and HEV-RNA.ResultsAnti-HEV IgG positive serology was found in 4 HIV-infected patients (1.5%) and 3 KT-patients (6.5%), leading to an overall seroprevalence of 2.3%. HEV-RNA detection was not observed among 55 HIV-patients at higher risk of chronic HEV (<200 CD4 cells/mm³, elevated alanine aminotransferase (ALT) levels, and/or positive anti-HEV antibodies) and among 44 KT-patients. None of the seven patients had anti-HEV IgM antibodies, thereby excluding any acute infection. The IgG avidity index confirmed past HEV infection among tested patients.ConclusionsThe low seroprevalence observed in the Paris region does not warrant a systematic evaluation of HEV infection in immunocompromised patients. However, HEV infection must be examined as a possibility if unexplained increases in ALT should occur and after more common viral hepatitis infections are excluded.